Jens Schlossmann

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 9

Top Topics

Structural Basis

Pulmonary Fibrosis

Top Venues

International journal of molecular sciences

British journal of pharmacology

Naunyn-Schmiedeberg's archives of pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Sally Prüschenk, Michael Majer, Jens Schlossmann
Novel Functional Features of cGMP Substrate Proteins IRAG1 and IRAG2. International journal of molecular sciences 24 (12) (2023)
Sally Prüschenk, Michael Majer, Jens Schlossmann
Novel Functional Features of cGMP Substrate Proteins IRAG1 and IRAG2. International journal of molecular sciences 24 (12) (2023)
Sally Prüschenk, Michael Majer, Jens Schlossmann
Novel Functional Features of cGMP Substrate Proteins IRAG1 and IRAG2. International journal of molecular sciences 24 (12) (2023)
Sally Prüschenk, Jens Schlossmann
Function of IRAG2 Is Modulated by NO/cGMP in Murine Platelets. International journal of molecular sciences 23 (12) (2022)
Jens Schlossmann
Editorial of the Special Issue: cGMP-Signaling in Cells and Tissues: Molecular, Functional and Pharmacological Aspects. International journal of molecular sciences 23 (12) (2022)
Sally Prüschenk, Michael Majer, Rainer Schreiber, Jens Schlossmann
IRAG2 Interacts with IP 3 -Receptor Types 1, 2, and 3 and Regulates Intracellular Ca 2+ in Murine Pancreatic Acinar Cells. International journal of molecular sciences 22 (24) (2021)
Michael Majer, Sally Prueschenk, Jens Schlossmann
Loss of PKGIβ/IRAG1 Signaling Causes Anemia-Associated Splenomegaly. International journal of molecular sciences 22 (11) (2021)
Manuela Harloff, Sally Prüschenk, Roland Seifert, Jens Schlossmann
Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice. British journal of pharmacology (2021)
Veronika Wetzl, Elisabeth Schinner, Frieder Kees, Lothar Faerber, Jens Schlossmann
Differences in the renal antifibrotic cGMP/cGKI-dependent signaling of serelaxin, zaprinast, and their combination. Naunyn-Schmiedeberg's archives of pharmacology 390 (9) (2017)